Infectious Diseases and Therapy (Jun 2024)
Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies
- Chris Wynne,
- Abundio Balgos,
- Jingxin Li,
- Paul Hamilton,
- Louie Tirador,
- Anjuli May Jaen,
- Chen Mo,
- Zijing Yue,
- Ying Ma,
- Qingshuang Wang,
- Rendu Wen,
- Zheng Yao,
- Jiaping Yu,
- Wenrong Yao,
- Jianhui Zhang,
- Hui Zheng,
- Kunxue Hong,
- Fengcai Zhu,
- Yong Liu
Affiliations
- Chris Wynne
- New Zealand Clinical Research
- Abundio Balgos
- Philippines Clinical Research, The Health Centrum
- Jingxin Li
- NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention)
- Paul Hamilton
- New Zealand Clinical Research
- Louie Tirador
- Philippines Clinical Research, St. Paul’s Hospital
- Anjuli May Jaen
- Philippines Clinical Research, The Medical City Iloilo
- Chen Mo
- Jiangsu Recbio Technology Co., Ltd.
- Zijing Yue
- Jiangsu Recbio Technology Co., Ltd.
- Ying Ma
- Jiangsu Recbio Technology Co., Ltd.
- Qingshuang Wang
- Jiangsu Recbio Technology Co., Ltd.
- Rendu Wen
- Jiangsu Recbio Technology Co., Ltd.
- Zheng Yao
- Jiangsu Recbio Technology Co., Ltd.
- Jiaping Yu
- Jiangsu Recbio Technology Co., Ltd.
- Wenrong Yao
- Jiangsu Recbio Technology Co., Ltd.
- Jianhui Zhang
- Jiangsu Recbio Technology Co., Ltd.
- Hui Zheng
- School of Public Health, Southeast University
- Kunxue Hong
- Jiangsu Recbio Technology Co., Ltd.
- Fengcai Zhu
- NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention)
- Yong Liu
- Jiangsu Recbio Technology Co., Ltd.
- DOI
- https://doi.org/10.1007/s40121-024-00998-z
- Journal volume & issue
-
Vol. 13,
no. 7
pp. 1723 – 1724
Abstract
No abstracts available.